{"schema_version":"1.0","type":"article","title":"Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy","url":"https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.md","lang":"en","date":"2026-06-20","publish_at":"2026-06-20T08:00:00+08:00","updated_at":"2026-06-20","category":"商業分析系列","topic":"商業分析系列","tags":["Enlivex","RAIN token","Biotech treasury","Crypto","Capital markets"],"summary":"Enlivex's paper gain from RAIN tokens shows how fragile biotech business models can create unusual treasury stories when operating revenue is absent and capital markets are difficult.","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"Biotech treasury shock","url":"https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury-en/figure-01.png"},{"alt":"Why it matters","url":"https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury-en/figure-02.png"},{"alt":"The real test","url":"https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury-en/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-20）。Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy。https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-20-enlivex-rain-token-biotech-treasury.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}